



## **Our PKG® will inform every clinical decision in Parkinson's. Every time.**

We reliably inform clinical decisions in Parkinson's because we know more about Parkinson's pathology and progression than any other company. We are on a trajectory to revolutionize the management of Parkinson's disease by enabling informed treatment decisions which are based on continuous and objective measurement of patients' key movement symptoms in everyday environments.

Our PKG technology:

- Technically de-risked and established in market – **over 3,000,000 hours of continuous Parkinson's monitoring delivered to date, representing more than 32,000 patient PKGs**
- Changes clinical decisions more than 50% of the time
- Boasts significant key opinion leader support
- Is underpinned by robust clinical validation and regulatory clearance through FDA 510(k) in the USA, CE mark in Europe, TGA ARTG 236583 listed

**For every diabetic patient, at every appointment, every doctor requires an accurate and current blood glucose assessment to support their clinical decisions. Our vision is that for every Parkinson's patient, at every appointment, every doctor will require a PKG.**

**Global Kinetics Corporation – proudly partnering for treatment of Parkinson's.**

## **Parkinson's pathology market**

Parkinson's disease (PD) is a fluctuating disorder that has relied on subjective, point in time observation and assessment to guide therapeutic decisions. Effective treatments exist for PD; however, selecting and titrating those treatments is difficult given the limited information gained from subjective, patient-reported symptomology. It is estimated that up to 80% of PD patients are uncontrolled. Uncontrolled patients have lower Quality of Life and cost the health care system twice as much as that of controlled patients. This problem has been resolved with the use of the Personal KinetiGraph® (PKG®), an innovative mobile health technology, developed by Global Kinetics.

**The PKG is the World's only FDA cleared continuous, objective, ambulatory assessment of the treatable disabling symptoms of Parkinson's. This leads to more informed treatment decisions, potentially better quality of life and reduced costs.**

- Market leader in clinical decision support for Parkinson's
- Defined path to reimbursement and profitability
- Preferred partner for therapy providers globally
- Diverse opportunities beyond provision of routine clinical care
- Technically de-risked and providing the only continuous ambulatory measure of key Parkinson's symptoms

## **Directors**

Mr John E. Schellhorn

Dr. J. Leighton Read, BSc, MD

Dr Amanda Gillon Bsc (Hons), PhD

Dr. Thomas Lönngrén  
PhD h.c. MRPharmS, FRCP

Dr. Christopher D. Nave,  
BSc (Hons), PhD

## **Executive team**

President and CEO:  
John E. Schellhorn

Chief Operating Officer, GM China:  
Brooke Ren PhD

Vice President, Clinical Affairs and Reimbursement:  
Peter M. Lynch, MPH

Senior Vice President, Business Partnering & Strategy:  
Michelle A. Goldsmith, LLB (Hons), BSc

Vice President, Product Development:  
Brendan Fafiani, BSc (Hons)

Senior Vice President, Global Marketing:  
Teresa Prego, MBA


## Corporate overview

Status	Privately-held Australian company
Locations	Australia (headquarters), USA and European Union
Personnel	42 FTE (Australia 25; USA 8; Europe Union 9)
Industry/sector	Neurology - Parkinson's disease and other movement disorders


### Global Market Opportunity for Routine Clinical Care

PD is a progressive and disabling neurological condition leading to potential loss of employment, loss of independence and eventually nursing home care. It is the second most common neurodegenerative disease after Alzheimer's disease. With increasing longevity and demographics, the prevalence of PD will unfortunately increase.

#### Estimated individuals over 50 world-wide with Parkinson's<sup>1</sup>



#### Estimated number of people eligible for PKG by region



### Focus on PKG for Device Assisted (Advanced) Therapies

Device Assisted (Advanced) Therapies (DATs) represent a high value, high growth segment in Parkinson's care. DATs include Deep Brain Stimulation (DBS) and Duodopa® and Apomorphine infusional therapies. The DAT segment is conservatively estimated to contribute US\$5billion in net global revenues to DAT partners in FY2018.


For DAT partners, PKG is already helping them grow their market, differentiate and enable new value-added services in PD by:

- Finding more and better candidates for DAT
- Improving DAT optimization to increase productivity, patient experience and retention
- Supporting payor submissions and new value based care approaches

### Pathways to Recurrent Funding

GKC has successfully secured recurrent funding in several European countries. With long term growth and high volumes in mind, GKC is focussed on demonstrating the clinical and health economic value of the PKG in order to accelerate reimbursement in the US and other countries. Our path to our reimbursement in the US is well underway, the American Medical Association has issued codes which will be operative from January 1st 2019.

### PKG for DAT Optimization - simplifying clinical management of DAT for better patient outcomes



\*Option to extend PKGs until optimized

### Partnership Offering

GKC partners with leading international healthcare and technology companies to:

- reduce the time and cost of clinical studies
- identify patients for their therapies through screening protocols
- optimise and personalise therapy; and
- introduce new methods of service delivery

PKG® is Personal KinetiGraph in the USA and Parkinson's KinetiGraph® in the rest of the world. PKG® and KinetiGraph® are registered trademarks of Global Kinetics Pty. Ltd.

Global Kinetics Pty. Ltd.  
Level 9/31 Queen Street Melbourne Victoria, Australia 3000.  
info@globalkineticscorp.com | www.globalkineticscorp.com



References - 1. Dorsey et. al (2007) "Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030." Neurology 2007; 68; 384-386.